Innovative strategies for improving CAR-T cell therapy: A nanomedicine perspective.
10.1097/CM9.0000000000003706
- Author:
Mengyao WANG
1
;
Zhengyu YU
1
;
Liping YUAN
2
;
Peipei YANG
1
;
Caixia JING
1
;
Ying QU
1
;
Zhiyong QIAN
2
;
Ting NIU
1
Author Information
1. Department of Hematology, Institute of Hematology, West China Hospital, Sichuan University, 37 GuoXueXiang Street, Chengdu, Sichuan 610041, China.
2. State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China.
- Publication Type:Review
- Keywords:
Chimeric antigen receptor T cell therapy;
Implantable scaffolds;
Nanoparticles;
Non-viral transduction;
Photothermal therapy
- MeSH:
Humans;
Nanomedicine/methods*;
Receptors, Chimeric Antigen/metabolism*;
Immunotherapy, Adoptive/methods*;
T-Lymphocytes/immunology*;
Nanoparticles/chemistry*;
Animals
- From:
Chinese Medical Journal
2025;138(21):2769-2782
- CountryChina
- Language:English
-
Abstract:
Chimeric antigen receptor T (CAR-T) cells have reshaped the treatment landscape of hematological malignancies, offering a potentially curative option for patients. Despite these major milestones in the field of immuno-oncology, growing experience with CAR-T cells has also highlighted several limitations of this strategy. The production process of CAR-T cells is complex, time-consuming, and costly, thus leading to poor drug accessibility. The potential carcinogenic risk of viral transfection systems remains a matter of controversy. Treatment-related side effects, such as cytokine release syndrome, can be life-threatening. And the biggest challenge is the inadequate efficacy related to poor infiltration and retention of CAR-T cells in tumor tissues and impaired T cell activation caused by the immunosuppressive tumor microenvironment (TME). Innovative strategies are urgently needed to address these problems, and nanomedicine offers good solutions to these challenges. In this review, we provide a comprehensive summary of recent advancements in the application of nanomaterials to enhance CAR-T cell therapy. We examine the role of innovative nanoparticle-based delivery systems in the production of CAR-T cells, with a particular focus on polymeric delivery systems and lipid nanoparticles (LNPs). Furthermore, we explore various strategies for delivering immune stimulators, which significantly enhance the efficacy of CAR-T cells by modulating T cell viability and functionality or by reprogramming the immunosuppressive TME. In addition, we discuss several novel therapeutic approaches aimed at mitigating the adverse effects associated with CAR-T therapies. Finally, we offer an integrated perspective on the future challenges and opportunities facing CAR-T therapies.
